Previous 10 | Next 10 |
FLORENCE, Italy and BOSTON, June 06, 2022 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced the presentation at the 2022 American Society of Clinical...
Urges Stockholders to Vote “FOR” Radius’ Highly Qualified, Independent Director Nominees – Catherine J. Friedman, Jean-Pierre Garnier, Ph.D. and Andrew C. von Eschenbach, M.D. – on the BLUE Proxy Card Details Company’s Signif...
Radius Health (NASDAQ:RDUS) is ending development of the abaloparatide transdermal system, a patch version of its osteoporosis injection Tymlos, after the U.S. FDA said an additional pivotal trial is necessary. Shares are down 6% in after-hours trading. The company said a new trial ...
Company ascertained regulatory clarity for possible forward progression of abalo-TDS Additional and successful clinical trial would be required to advance towards an NDA filing New timeline for earliest possible abalo-TDS launch: 2H 2025 Based on regulatory clarity, timeline, ...
Further Expands Board’s Expertise and Gender Diversity Enhances Corporate Governance BOSTON, May 20, 2022 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) today announced that it has added two new independent members to the Board of...
Elacestrant, an oncologic under development from Radius Health (NASDAQ:RDUS) for ER+/HER2- breast cancer, met its primary endpoint of progression-free survival ("PFS") in a phase 3 trial. Radius Health (RDUS) shares are up 6% in after-hours trading. The EMERALD trial enrolled patien...
EMERALD study met both its primary end points of progression-free survival (PFS) in overall population and in ESR1 mutated patients PFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population, and 26.8% vs. 8.2% in the ESR1 mutation population Da...
Gainers: Celularity CELU +10%. Purple Biotech (PPBT) +8%. BioSig Technologies (BSGM) +4%. Concert Pharmaceuticals (CNCE) +4%. Molecular Partners (MOLN) +4%. Losers: Baudax Bio BXRX -28%. Doximity DOCS -9%. Radius Health (RDUS) -7%. N...
The following slide deck was published by Radius Health, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Radius Health, Inc. 2022 Q1 - Results - Earnings Call Presentation
Radius Health, Inc. (RDUS) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Company Participants Ethan Holdaway - Head of Investor Relations Kelly Martin - President and CEO Mark Conley - Chief Financial Officer Bob Valentine - Strategic Business Officer Chhaya Shah - Senior Vice Presi...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 54.4% to $0.4264 on volume of 158,036,142 shares Versus Systems Inc. (VS) rose 73.5% to $2.29 on volume of 40,036,424 shares Tesla Inc. (TSLA) rose 5.3% to $220.97 on volume of 32,375,487 shar...
Ferrous, Nonferrous and Finished Steel Sales Volumes Up Sequentially Radius Board Declares Quarterly Dividend PORTLAND, Ore., July 02, 2024 (GLOBE NEWSWIRE) -- Radius Recycling, Inc. (NASDAQ: RDUS) today reported results for the third quarter of fiscal 2024 ended May 31, 2024. ...